Thus, treatment with the SHH antagonist GDC-0449 (Vismodegib), which specifically targets medulloblastoma of granule cell origin driven by SHH expression, had no effect on MYCN and failed to reduce clonogenic capacity or growth of GTML/Trp53KI/KI-derived medulloblastoma neurospheres (Figures S4A, S4B, and S4E). This evidence concerns the gene MYCN and medulloblastoma.